Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
May 23 2024 - 1:00AM
Business Wire
- Restylane® VOLYME™ is designed for contouring and volumization
of the mid-face region to support patients in achieving a youthful,
revitalized look
- The complementary Shape Up Holistic Individualized Treatment
(HIT™) has also been introduced in China, empowering aesthetics
practitioners to deliver dynamic and natural mid-face solutions for
their patients
- Galderma is committed to delivering its world-leading portfolio
of innovative aesthetics solutions to China as well as other
countries and regions around the world
Galderma (SWX:GALD) announced today the launch of its hyaluronic
acid injectable filler, Restylane® VOLYME™ in China. The company is
also introducing its complementary Shape Up Holistic Individualized
Treatment (HIT™) in the country, which addresses aging concerns
caused by loss of structural support in the mid-face. The
availability of these targeted solutions for the mid-face region is
demonstrative of Galderma’s commitment to meeting patient and
injector needs in China. In the past decade, the growth of China’s
aesthetics medicine market has outpaced the global market; with
relatively low market penetration, there remains significant
potential for future growth.1
Developed using Galderma’s proprietary OBT™* gel technology,
Restylane® VOLYME™ is indicated for the correction of mid-face
volume deficit and/or mid-face contour deficiency through
injections into the subcutaneous to supraperiosteal layers of the
skin.2-3 Hyaluronic acid fillers are often patients’ first choice
for mid-face augmentation and have been shown to deliver high
patient satisfaction and long-lasting effects.4 In China,
hyaluronic acid fillers are among the top 10 most-sold aesthetics
products.1
“We are delighted to deliver
Galderma’s innovative aesthetics solutions in China with the
support of our research and development teams, as well as local
partners and regulatory authorities. As the Chinese market
continues to expand, we look forward to working closely with all
stakeholders to deliver our full, premium range of aesthetics
products to meet the varied and individual needs of patients and
injectors.”
GERRY MUHLE HEAD OF
GLOBAL PRODUCT STRATEGY GALDERMA
Developed with a global community of injectors, the Shape Up
HIT™ is the latest of Galderma’s HITs™ to be introduced in China,
designed to create a common language to facilitate a two-way
dialogue between patient and practitioner to align on patient
priorities and keep satisfaction at the forefront.
"Aesthetic plastic surgery is an
artistic creation under medical
constraints, embodying a holistic
and individualized approach. Facial expressions are controlled by
42 muscles which convey emotions such as joy, anger, sorrow, and
happiness. These muscles are also involved in language, chewing,
and other activities. The appearance of the mid-face is crucial in
interpersonal communication. Together, Restylane® VOLYME™ and the
Shape Up HIT™ enable patients to maintain their natural facial
expressions while also supporting injectors to deliver a youthful
and long-lasting aesthetic effect."
PROFESSOR HAIYAN CUI
DIRECTOR OF THE INSTITUTE OF AESTHETIC PLASTIC SURGERY AND
MEDICINE TONGJI UNIVERSITY
DIRECTOR OF THE PLASTIC &
COSMETIC SURGERY DEPARTMENT TONGJI HOSPITAL OF TONGJI
UNIVERSITY
HIT™ is an individualized treatment approach which enables
injectors to leverage their expertise with the renowned Galderma
Restylane® portfolio to optimize aesthetic outcomes while
prioritizing patient satisfaction. The Balanced Profile HIT™ was
Galderma’s first HIT™ to be introduced in China in 2023, providing
a framework for practitioners to conduct a full objective facial
assessment for the patient and help bring balance to their profile.
HIT™ naturally springboards from Galderma’s AART™ (Assessment,
Anatomy, Range, Treatment) methodology for a new generation of
individualized aesthetics.
Restylane® is the largest and most diverse range of individually
engineered hyaluronic acid fillers on the market, approved in more
than 80 countries and regions, and with over 65 million treatments
administered worldwide.5-8
About Galderma Galderma (SIX: GALD) is the emerging
pure-play dermatology category leader, present in approximately 90
countries. We deliver an innovative, science-based portfolio of
premium flagship brands and services that span the full spectrum of
the fast-growing dermatology market through Injectable Aesthetics,
Dermatological Skincare and Therapeutic Dermatology. Since our
foundation in 1981, we have dedicated our focus and passion to the
human body’s largest organ – the skin – meeting individual consumer
and patient needs with superior outcomes in partnership with
healthcare professionals. Because we understand that the skin we
are in shapes our lives, we are advancing dermatology for every
skin story. For more information: www.galderma.com
Notes and references:
* Optimal Balance Technology – OBT
- Deloitte. China Aesthetic Medicine Outlook Report. Accessed May
2024. Available online.
- Talarico S et al. High patient satisfaction of a hyaluronic
acid filler producing enduring full-facial volume restoration: An
18-month open multicenter study. J Dermatol Surg. 2015; 41:
1361-1369.
- Galderma. Restylane Instructions for Use.
- Trinh LN & Gupta A. Hyaluronic acid fillers for midface
augmentation: A systematic review. Facial Plast Surg. 2021; 37(5):
576-584.
- Öhrlund A. New method to study the balance of firmness and
flexibility for HA fillers. Poster presented at AMWC 2019.
- Galderma. Data on file. MA-57232.
- Galderma. Data on file. MA-33939.
- Galderma. Data on file. QMS-3637.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522425104/en/
For further information:
Christian Marcoux, M.Sc. Chief Communications Officer
christian.marcoux@galderma.com +41 76 315 26 50
Sébastien Cros Corporate Communications Director
sebastien.cros@galderma.com +41 79 529 59 85
Emil Ivanov Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com +41 21 642 78 12
Jessica Cohen Investor Relations and Strategy Director
jessica.cohen@galderma.com +41 21 642 76 43